Repatha, Similar Cholesterol Drugs, Overpriced For Benefits They Provide: Study

A new study warns that Repatha and similar new cholesterol drugs may be significantly overpriced in the U.S. due to the limited benefits patients may receive from these injectable medications. 

Researchers with the University of California San Francisco found that Repatha and similar cholesterol drugs may be overpriced by as much as 71% in the U.S., even though they are far more reasonably priced in Europe and elsewhere. Their findings were published on August 23 in the medical journal JAMA Cardiology.

Repatha (evoluocumab) is an injection drug approved in 2015 for the lowering of LDC cholesterol; so-called “bad” cholesterol. It is manufactured by Amgen and belongs to a relatively new class of cholesterol drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. The class also includes the drug Praluent (alirocumab).

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Researchers looked at the costs of Repatha, U.S. clinical practices, background therapy, event rates, risk factors and more to determine the cost effectiveness based on the amount spent per quality of life years gained.

According to the researchers’ model, at an annual cost of just over $14,000 per patient in the U.S., the health care system would have to spend $450,000 per year on Repatha for every one year of quality of life gained for one patient. To bring the cost down to something that is actually cost-effective, Amgen would have to drop the price of Repatha to between $9,669 and $6,780 per year, the researchers determined.

That target cost is how much Repatha actually costs in Europe, where many countries have a single-payer health care system. However, Amgen is able to charge substantially more for the cost of the exact same drug here in the United States. That cost is born by patients and their insurance companies, though the amount patients pay can vary widely, with copays ranging from about $380 per month for some patients, while those with good prescription drug coverage may pay nothing at all.

“At its current list price of $14,523, the addition of evolocumab to standard background therapy in patients with atherosclerotic cardiovascular disease exceeds generally accepted cost-effectiveness thresholds,” the researchers concluded.

It is not the first time researchers have raised warnings about Repatha’s costs.

In a 2015 report for the Institute for Clinical and Economic Review (ICER), researchers warned that while Repatha and Praluent were effective, their $14,000 per year price tag appeared to be excessive compared to the health benefits they provided. That report determined that the price of these two drugs raised “serious questions” as to whether they were a sensible value to patients and the health care system.

1 Comments

  • JoanFebruary 21, 2022 at 12:53 pm

    Lost of muscles

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.